Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2Sign in
← Cases

Tepotinib

3a6f63ac-9efa-51bd-8c7b-5b52620fd746 · FDA Approved · targets C_MET

Tepotinib

MeasuredReference

Tepotinib targets C_MET, NTRK3. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

Top hallmarks

  • tumor promoting inflammation1.4k
  • proliferation1.2k
  • evading apoptosis1.2k

Top pathways disrupted

  • pi3k akt mtor signaling2.8k
  • apical junction2.2k
  • apoptosis2.1k

Resistance landscape — Tepotinib

MeasuredReference

10 known oncogenic variants exist on Tepotinib's top targets — see detail for inhibition impact.

Open in new tab